News stories about Solid Biosciences (NASDAQ:SLDB) have been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Solid Biosciences earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.2010628656015 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
SLDB has been the subject of a number of analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 price target on shares of Solid Biosciences in a report on Sunday, June 24th. Zacks Investment Research raised Solid Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. Leerink Swann raised their price target on Solid Biosciences from $14.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, May 10th. Nomura raised their price target on Solid Biosciences from $37.00 to $57.00 and gave the stock a “buy” rating in a report on Monday, June 25th. Finally, Credit Suisse Group initiated coverage on Solid Biosciences in a report on Thursday. They issued a “neutral” rating and a $38.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $45.14.
Shares of SLDB stock traded up $0.54 on Friday, reaching $40.19. The company’s stock had a trading volume of 861 shares, compared to its average volume of 122,727. Solid Biosciences has a 12-month low of $6.83 and a 12-month high of $54.84. The company has a market capitalization of $1.56 billion and a PE ratio of -14.02.
Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Friday, August 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.01). sell-side analysts predict that Solid Biosciences will post -2.21 earnings per share for the current fiscal year.
About Solid Biosciences
Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.
Recommended Story: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.